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Abstract: The detection of molecular alterations is crucial for the individualized treatment of advanced
non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major impact on
patient’s progression free and overall survival. Although laboratory testing for molecular alterations
has continued to improve; little is known about how biopsy technique affects the detection rate of
different mutations. In the retrospective study detection rate of epidermal growth factor (EGFR)
mutations in tissue extracted by bronchoscopic cryobiopsy (CB was significantly higher compared to
other standard biopsy techniques. This prospective, randomized, multicenter, single blinded study
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evaluates the accuracy of molecular genetic characterization of NSCLC for different cell sampling
techniques. Key inclusion criteria are suspected lung cancer or the suspected relapse of known NSCLC
that is bronchoscopically visible. Patients will be randomized, either to have a CB or a bronchoscopic
forceps biopsy (FB). If indicated, a transbronchial needle aspiration (TBNA) of suspect lymph nodes
will be performed. Blood liquid biopsy will be taken before tissue biopsy. The primary endpoint is
the detection rate of molecular genetic alterations in NSCLC, using CB and FB. Secondary endpoints
are differences in the combined detection of molecular genetic alterations between FB and CB, TBNA
and liquid biopsy. This trial plans to recruit 540 patients, with 178 evaluable patients per study cohort.
A histopathological and molecular genetic evaluation will be performed by the affiliated pathology
departments of the national network for genomic medicine in lung cancer (nNGM), Germany.
We will compare the diagnostic value of solid tumor tissue, lymph node cells and liquid biopsy for
the molecular genetic characterization of NSCLC. This reflects a real world clinical setting, with
potential direct impact on both treatment and survival.
Keywords: NSCLC; molecular genetic characterization; bronchoscopy; cryobiopsy; forceps biopsy;
next generation sequencing
1. Background
Lung cancer is one of the most common cancers, with 230,000 new diagnoses per annum in
the United States and 410,000 in Europe, with a prevalence of approximately 1.8 million patients
worldwide [1–4]. Non-small cell lung cancer (NSCLC) accounts for 75–85% of all lung cancers [5].
Two thirds of these patients are diagnosed in non-curable stage III or IV, and are usually treated
systemically [6–8]. During the last decade, the systemic treatment has developed from a monomorphic
platinum-based chemotherapy to a broad spectrum of individually tailored therapeutic approaches,
based on the molecular tumor characterization of each patient [9]. NSCLC characterization is
aligned to the existing specific therapeutics, but there are now rapidly developing new treatment
options [10]. Patients’ individualized treatment becomes more effective, not only because of the broader
therapeutic spectrum, but also with the increase of progression free and overall survival (in certain
situations) [11–18]. In addition, side effect profiles are better for most targeted drugs compared to
the earlier chemotherapy [12–14,19–21]. However, detection of a distinct mutation, aberration or
translocation of the tumor cells and the evidence of a specific immunoreactivity, as determined by
the expression of programmed death-receptor 1 (PD-1) and its ligand (PD-L1) on tumor cell surface
(PD-L1) or patients’ T-cells (PD-1), are crucial to predict therapeutic effectiveness. So, the detection of
a targetable structure predicts therapeutic response and therefore opens up the therapeutic window
that would otherwise stay closed.
As a consequence, precise and correct characterization of the molecular genetic profile in patients
with non-curable advanced stage III and IV NSCLC is crucial for ensuring optimal treatment; missing
any targetable alteration may result in suboptimal therapy and could even impair patients’ overall
outcome. Molecular genetic tumor characterization may also be of importance in earlier tumor stages.
Although tumor analytics are claimed to be refined and sensitized down to a single cell level,
thus enabling facilitated tumor detection and characterization in the peripheral blood [22], the clinical
relevance of this approach analyzing a huge number of cells is unclear. Furthermore, the detection
of a single tumor cell type does not necessarily reflect the tumor, with its inherent heterogeneity,
since NSCLC tumor heterogeneity has been known and characterized in various studies for a long
time [23–34]. However, such considerations have rarely been addressed in therapeutically oriented
studies. More stringent tumor tissue requirements as a basis for tumor characterization have, up
to now, been only vaguely specified or not specified at all, even in large studies or international
guidelines [10,35–37]. So, there is a definite need to optimize tissue analytics to provide representative
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tumor characterization; but there is also currently a lack of a ‘gold standard’ for evaluation of this
approach [38]. Although large tumor specimens are generally preferred for mutation assays [36];
the required sample size has not been evaluated in the past.
Cryobiopsy (CB) has already been confirmed to be superior to forceps biopsy (FB) for
histopathological evaluation of endobronchial malignancies in a prospective study [39]. A retrospective
study [40] has confirmed that there is a significant increase in epidermal growth factor (EGFR) detection
rate for CB compared to FB, but CB and FB have not yet been compared in terms of molecular
genetic tumor characterization. Therefore, we have designed the PROFILER study to compare both
bronchoscopic tissue sampling techniques (CB and FB), transbronchial needle aspiration (TBNA)
and liquid biopsy for their diagnostic yield in NSCLC.
2. Methods/Design
2.1. Trial Design
The PROFILER study is a prospective, multicenter, randomized, single blinded trial in accordance
with the German Medical Association Professional Code. It has been designed to evaluate the accuracy
of molecular genetic characterization of NSCLC, with the primary aim being to detect the best biopsy
technique for tumor cell profiling. Five university hospitals or lung cancer centers across Germany will
participate in the study. The enrolment of 356 evaluable patients is planned (Figure 1) with 178 patients
having either CB or FB. Based on the study protocol Version 2.9, this study is currently recruiting
(the first subject being enrolled on 19 December 2018). The PROFILER study has been registered on
www.clinicaltrials.gov; NCT03971175.
2.2. Patient Selection
Patients with primary diagnosis of suspected, centrally localized lung cancer, or patients with
known NSCLC and suspected relapse after therapy, form the study population. Inclusion and exclusion
criteria are shown in Table 1A,B.
2.3. Study Objectives
The primary objective is to assess differences in detection of molecular genetic alterations in
NSCLC between FB and CB (Figure 2).
The secondary objectives assess differences in the detection of molecular genetic alterations in
NSCLC between liquid biopsy, solid tumor tissue biopsy obtained by bronchoscopic techniques,
cytological material obtained by TBNA, and to compare combined methods (tissue biopsy, TBNA
and liquid biopsy) with single techniques, to evaluate differences between naïve and processed
tumor tissue specimens (e.g., by microdissection), and finally, to assess differences in side effects
(e.g., peri-interventional bleeding).
The exploratory objectives analyze tumor mutational burden with regard to solid tumor tissue by
FB or CB and cytologic material by TBNA and liquid biopsy.
2.4. Pre-Procedural Training and Standardization
All centers are already expert in the use of both forceps and cryobiopsy. Due to the integration
or affiliation to the national network for genomic medicine lung cancer in Germany (nNGM), all
participating pathologists will use the same standard for evaluation.
2.5. Procedural Protocol
2.5.1. Patient Enrollment
The local investigators pre-screen any potential participant with pulmonary lesions which were
suspicious of lung cancer, or known NSCLC with suspected relapse or progression, in accordance
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with the inclusion and exclusion criteria; after giving informed consent, patients are eligible for study
entry. Bronchoscopy is undertaken according to local standards, and in accordance with the published
guidelines [41,42]. If endobronchial tumor is visible and reachable, inclusion criterion 4 is fulfilled,
and the patient can be included in the study. A study flow chart is shown in Figure 1.Diagnostics 2020, 10, x FOR PEER REVIEW 4 of 16 
 
 
Figure 1. Flow chart of applied techniques and procedures. Assignment of colors: forceps biopsy—
green; cryobiopsy—blue; (EBUS-) TBNA—yellow; liquid biopsy—red; (EBUS-) TBNA—
endobronchial ultrasound guided transbronchial needle aspiration; NSCLC—non-small cell lung 
cancer; SCLC—small cell lung cancer. 
2.2. Patient Selection 
Patients with primary diagnosis of suspected, centrally localized lung cancer, or patients with 
known NSCLC and suspected relapse after therapy, form the study population. Inclusion and 
exclusion criteria are shown in Table 1A,B. 
  
Figure 1. Flow chart of applied techniques and procedures. Assignment of colors: forceps biopsy—green;
cryobiopsy—blue; (EBUS-) TBNA—yellow; liquid biopsy—red; (EBUS-) TBNA—endobronchial ultrasound
guided transbronchial needle aspiration; NSCLC—non-small cell lung cancer; SCLC—small cell lung cancer.
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Table 1. (A) shows Inclusion criteria of the study; (B) shows Exclusion criteria of the study.
(A) Inclusion Criteria
Informed consent to the study and the study-specific procedures prior to any study intervention
Age ≥ 18 years
Patients with known NSCLC and suspected relapse after therapy
Patients with known NSCLC and suspected relapse after therapy
Bronchoscopically visible tumor
(B) Exclusion Criteria
Pre-existing malignancy other than NSCLC
Contraindication for bronchoscopy follow the international guidelines [41,42], daily clinical practice and local
regulations, and exclude:
- Patients with existing or at risk of pulmonary and cardiovascular decompensation
- Patients at increased risk of bleeding with antiplatelet agents except aspirin (e.g., clopidogrel, ticlopidine),
anticoagulant therapy (abnormal PTT), thrombocytopenia (<50.000/µL) or coagulopathy (abnormal
in-vitro bleeding time)
- Intolerance to sedation
- Unstable or immobile cervical spine
- Limited motion of the temporomandibular joint
- Previous enrolment in the present study
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Figure 2. Examples of bronchoscopic forceps biopsy (A) and bronchoscopic cryobiopsy (B), as shown
in two of the study patients.
2.5.2. Randomization
Pati nts are randomized to either FB or CB for tis ue sampling by a stratified, balanced (1:1)
bl ck randomization, stratified by study site. The randomization will be prepared at the Institute
of Epidemiol gy and Medical Biometry, University of Ulm. Seal d envelopes will be prepar d for
se in every study site, containing the randomize group. The opening of an envelope ha to be
documented in detail on the case report form (CRF). Liquid biopsy is performed in every patient
included in the study, and TBNA is perfor ed if indicated, depending on local investigators’ deci ion,
irrespective of rand mization.
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2.5.3. Liquid Biopsy Procedure
Prior to any bronchoscopic intervention, blood is drawn for liquid biopsy analysis.
2.5.4. Bronchoscopy
Bronchoscopy is performed using either a flexible or rigid technique, depending on the operator’s
choice. In the case of flexible bronchoscopy, placement of an endotracheal tube is recommended in
order to provide a secure airway. When rigid bronchoscopy is used, a tissue biopsy is carried out using
a flexible bronchoscope inserted through the rigid tube. General anaesthesia will be used for rigid
bronchoscopy, and deep sedation and local anaesthesia for intubation with a flexible tube. Patients
will be monitored for oxygen saturation, ECG and repeated non-invasive blood pressure, according to
the local standards of each center.
2.5.5. Forceps and Cryobiopsy Procedure
Depending on randomization, forceps or cryobiopsy are performed, in accordance with
the guidelines and previous reports [39,41–44]. Forceps of a diameter between 1.8 and 2.6 mm
are used for FB; cryoprobes of 1.9 or 2.4 mm (Erbe Elektromedizin GmbH, Tübingen, Germany) are
used for CB. Freezing time for CB is dependent on the individual situation, morphology, localization,
size and probe positioning, and is determined by the local investigator. A minimum of four biopsies
will be taken.
2.5.6. TBNA Procedure
If indicated, TBNA is performed, preferentially under EBUS- guidance, to evaluate hilar
and mediastinal lymph node metastasis. In some cases, TBNA may be done without EBUS guidance.
EBUS equipment is not predefined by the study protocol; the procedure being performed according to
the local standard and guidelines [45,46].
2.6. Pathological Analysis
2.6.1. Baseline Pathological Evaluation
The histological, immunohistological and immunohistochemical evaluation of extracted solid
tissues by FB or CB, and the cytological, immunocytological and immuncytochemical evaluation of
TBNA extracted cytoblock or smear, are performed at the local pathological institute (including ALK,
ROS 1 and PD-L1 expression level on tumor cells). Histological and immunohistological tissue
evaluation, or cytological and immunocytological evaluation, assigns the tumor tissue to either
NSCLC or small cell lung cancer (SCLC). Any cases of SCLC will be excluded from further analyses
and classified as a ‘drop out’. For any NSCLC, further molecular genetic evaluation will be undertaken,
as described below.
Harmonization of the analytical processes is guaranteed in the study setting by the choice of
the individual institutes of pathology, which are partners in the German national network of genomic
medicine lung cancer (NGM lung cancer) [47], or which have participated in national collaborative ring
trials. Additional collaborative ring trials for the analytical process will be performed for a selection of
samples prior to the planned analytical process in this study.
2.6.2. Molecular Genetic Evaluation
Molecular genetic testing will be performed for solid bronchoscopically extracted material,
for the cytological specimen extracted by TBNA (if applicable), and for the liquid biopsy samples.
All currently targetable and non-targetable genetic aberrations, as suggested by the guidelines [10,35–37]
(mutations, fusions, copy number variation (CNV)), as well as other important prognostic markers,
are analyzed in accordance with the guidelines for standardized evaluation from the nNGM lung
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cancer consortium [48]. Targeted multigene mutation screening will be performed using different next
generation sequencing techniques and platforms, depending on the participating site:
Tübingen: Amplicon library preparation will be done using the nNGM Panel 1.0 and 2.0.
Semiconductor sequencing will be performed according to the manufacturers’ manuals using the Ion
AmpliSeq Library Kit v2.0, the Ion 510 and Ion 520 and Ion 530 Kit—Chef and the Ion 520 Chip Kit
on the Ion GeneStudio S5 (Ion Reporter software) (Thermo Fisher Scientific, Waltham, MA, USA).
Fusion and CNV detection will be undertaken with immunohistochemistry following fluorescent in
situ hybridization, or with the Archer® FusionPlex Lung panel (Archer Analysis software, ArcherDX,
Boulder, CO, USA).
Hamburg: The NEOselect assay (NEO New Oncology, Cologne, Germany) is used to detect
single nucleotide mutations, copy number variations and fusions on the Illumina NextSeq system
(Illumina, San Diego, CA, USA), according to the manufacturers’ manual. In the case of very limited
material, CNVs will be tested using PCR technologies such as cobas®; fusion and CNV detection will
be undertaken with immunohistochemistry.
Köln: The amplification of DNA will be performed using the customized GeneRead DNAseq
custom Panel V2 with primers for the nNGM Panel 1.0 and 2.0 (Qiagen, Hilden, Germany), following
the manufacturer’s instructions. For library preparation, the Gene Read DNA Library I Core Kit
and the Gene Read DNA I Amp Kit (Qiagen) will be used. After end-repair and adenylation, libraries
were ligated to NEXTflex DNA Barcodes (Bio Scientific, Austin, TX, USA) and sequenced on the MiSeq
(Illumina, San Diego, CA, USA) with a MiSeq reagent kit V2 (300 cycles) (Illumina), following
the manufacturer’s recommendations. Data will be exported as FASTQ files. Alignment, variant calling
and annotation will be done using an in-house bioinformatic pipeline. A 5% cutoff for variant calls will
be used, and results will only be interpreted if the coverage was >200×. The detection of gene fusions
will either be done by a combination of immunohistochemistry and fluorescence in situ hybridization
(FISH), or by using the Archer® FusionPlex Lung panel with the Archer Analysis software (ArcherDX,
Boulder, CO, USA). CNVs will be analyzed by FISH.
Essen: The QIASeq Targeted DNA Panels (Qiagen, Hilden, Germany) nNGML1 and/or
nNGML1.2 [48] will be run on an Illumina MiSeq or Illumina NextSeq platform, and the CLC
Genomics Workbench versions 5.0.1, 12.0.3 or 20 will be used for data acquisition. Fusion and CNV
detection will be carried out by immunohistochemistry, FISH, or by using Archer® FusionPlex CTL
panel (ArcherDX, Boulder, CO, USA).
2.7. Safety Data
2.7.1. Bleeding
Bleeding is the most relevant side effect of any bronchoscopic biopsy and is categorized as shown
in Table 2.
Table 2. Periinterventional bleeding.
Category Intervention for Bleeding Control
No Self-limiting bleeding without need for any intervention for bleeding control
Mild Self-limiting bleeding, manageable with suction alone and without the need for anyspecific intervention
Moderate
Non self-limiting bleeding with need for suction plus additional intervention (alone or
in combination) including application of ice-cold saline or vasoconstrictors, or transient
balloon tamponade, leading to a termination of bleeding
Severe
Non self-limiting bleeding with need for suction, plus any additional intervention (alone or
in combination) and need for prolonged observation, stay in the hospital or intensive
care therapy
Persistent/Fatal Any persisting health impairment or death as a direct consequence of bleeding
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2.7.2. Other side Effects
In addition to bleeding, hypoxia, cardiac arrhythmia, fever, infection and any other event
attributable to the procedure will be evaluated.
2.8. Statistical Methodology
All analyses will be performed by the independent Institute of Epidemiology and Medical
Biometry, Ulm University, after database lock and unblinding. A comprehensive statistical analysis
plan (SAP) will be prepared prior to a first analysis of the study data.
2.8.1. Sample Size Estimate
Sample size calculation is based on the comparison of the detection rates for both techniques
(FB and CB). Based on our earlier retrospective study, the cryobiopsy detection rate of EGFR was
increased by approximately 50%, from 14% to 21% [40]. As our primary endpoint combines various
aberrations, including PD-L1-expression level, a rate of detectable alterations of around 40% could be
expected. With an expected relative increase of almost 50% for aberrations, related to a frequency of
40%, an absolute detection frequency of 55% was considered to be a conservative estimate.
The following assumptions were made for the sample size calculation: two-sided Chi-square
test, type one error alpha = 0.05, power = 0.80. With a detection rate of 40% in the control FB
group, and a conservative estimation of the detection rate of 55% in the experimental CB-group,
and an assumption of equal number of patients in each group, 173 patients are required for each group,
i.e., 2 × 173 = 346 patients in the whole trial.
Because of the short duration of observation in each patient, the rate of loss to follow up is very
small. To allow a drop-out rate of up to 3% 10 extra patients need to be recruited, resulting in a total
sample size of 356 patients. As seen in Figure 1, the sample size for recruitment has to be increased,
because NSCLC is likely to form 80% of all tumors; about 45 will be small cell lung cancer (SCLC)
and about 10% (25 cases) would not be diagnostic in each cohort. Therefore, 2 × 248 patients will be
required for randomisation. Although there is no current data, it can be assumed that in some cases
an endobronchial tumor will not be visible. As a rough estimate, we assume that in 8% of the cases
(n = 44), it will not be possible to take a biopsy from the central airways. This therefore determines that
the total number of recruited suspected lung cancer patients is 540.
Sample size calculation was performed by nQuery Advanced 8.1.
2.8.2. Randomization
The equality of study arms will be achieved by a stratified, balanced (1:1) block randomization.
Randomization will be stratified according to study site. The randomization will be undertaken
independently at the Institute of Epidemiology and Medical Biometry, University of Ulm, using
the randomization software ROM. Sealed envelopes are prepared for use in each study site,
which contain the randomized group.
2.8.3. Blinding
The study is single blinded, with the pathologists being blinded for the applied biopsy technique.
2.8.4. Primary Endpoint Analysis
The primary endpoint is the detection of at least one molecular genetic alteration in NSCLC.
Confirmatory and exploratory data analyses are performed for this dichotomous primary endpoint
as follows:
The difference in both groups based on the primary endpoint are evaluated using a Chi-square test
(two sided at a significance level of 5%). All further analyses of the primary endpoint will be performed
in an exploratory fashion. All results from these analyses will be regarded as hypothesis-generating,
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and not as proof of efficacy. Univariate and multiple logistic regression models to adjust for strata
(study site) and potential confounding variables will be performed.
2.8.5. Secondary Endpoint Analysis
The secondary, exploratory objectives and safety data are analysed by statistical methods for
comparison of two unpaired groups, as appropriate for the characteristic of the variables, e.g., chi-square
test for categorical and t-test/Mann–Whitney U test for continuous variables. The assessment of
the diagnostic value of liquid biopsy and TBNA, as both single techniques and in combination, will
be undertaken by logistic regression analysis and ROC analysis. In order to investigate effects of
subgroups and putative confounding factors, further analyses are performed, using generalized linear
regression models as appropriate.
2.9. Trial Oversight and Ethics Approval
All procedures including FB, CB, TBNA and blood extraction for liquid biopsy are standardized
routine and approved techniques using CE certified medical devices for diagnosis of lung cancer.
The diagnostic workflow and its results are analyzed in this study setting, but they will not be
altered at all, so all diagnostic procedures are performed as in routine clinical practice. This study
protocol follows the German Medical Association Professional Code with institutional review board
(IRB)-approval of the local IRB for each investigational site.
This clinical study is conducted in accordance with all appropriate laws and regulations, including,
but not limited to, the Guideline for Good Clinical Practice (GCP), the Code of Federal Regulations (CFR),
Directive 2001/20/EC, and the ethical principles of the Declaration of Helsinki and its amendments.
Nothing in this document limits the authority of a physician to provide emergency medical care
as appropriate.
This study was approved by the leading ethics committee at the University hospital of Tuebingen
(644/2018BO1) between 29 August 2018 and 12 December 2018, and approved by local ethics committees
at all participating study sites.
3. Discussion
As with many other malignancies, NSCLC cannot be considered as a single, monomorphic
disease, but rather as a general term for a variety of lung malignancies with different causes, behaviors
and prognoses which we are beginning to unravel. Existing and upcoming treatment options for many
specified subtypes target identical molecular genetic changes/characteristics as the ‘Achilles’ heel’ of
the tumor. Such treatments have dramatically changed management and prognosis of patients over
the last decade. However, to enable this increasingly individualized therapy, the exact characterization
of each underlying tumor is crucial. Without detection of a specific aberration, e.g. a sensitizing EGFR
mutation, the optimal targeted therapy would be ineffective [49–51]. On the other hand, missing
a molecular genetic aberration, even in a subset of tumor cells, has a relevant and large impact on
individual patients’ treatment and prognosis.
Current diagnostic approaches are intended to address this central point by their steadily increasing
sensitivity and specificity, ability to analyze the smallest tumor fragments and cytological material or
cell free DNA on a single cell level. In addition, there is a desire for easier tumor material extraction,
preferentially from the blood. Although this approach contradicts earlier guidelines for NSCLC
analysis [35,36], recent updates have focused on analytical techniques, displacing the role of tissue
patterns to the background [10,37]. Tumor heterogeneity may be considered by such approaches,
but the finding of any or several NSCLC clones does not guarantee that they represent the entire tumor.
Our previous observations have shown significant differences in EGFR detection between tumor
tissue samples extracted by various techniques in a retrospective analysis [40]. This raises the question
as to whether the diagnostic yield from different tissue or cytological sampling techniques differs,
and if so, to what extent? The diagnostic value for each sampling technique alone has often been
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addressed [52–64], but, to our knowledge, differences in NSCLC diagnoses have only been analyzed
between different techniques or biopsy sites [65,66], but not in a prospective multicenter study that
includes a large study cohort.
This PROFILER study approach uses the basic principles of tumor diagnostics, but takes into
account that even the best available diagnostic tool may only be as good as the starting material to
be analyzed [35,36]. In general, larger tumor specimens (e.g., resections) are preferred for mutation
assays, because of a greater amount of material and a greater capacity to enrich the malignant content
by dissection (as discussed in the molecular testing guideline by Lindeman et al.) [36] In the PROFILER
study, we compare the complete tumor characterization between FB and CB standard bronchoscopic
techniques as the primary endpoint. This concept goes far beyond existing comparisons [67–73],
focusing on the adequacy and representative nature of all cell containing specimens that can be acquired
for NSCLC diagnostics, since this has never been addressed in a prospective multicenter trial setting of
this size. These results allow determination of which single technique or a combination of techniques
best enables NSCLC tumor characterization.
Our study has some potential limitations that have to be addressed. The randomization to FB
or CB could lead to an imbalance of the two cohorts, e.g., in terms of patient characteristics, tumor
growth or stage, although the sample size should enable a good balance. The histological, cytological
and molecular genetic evaluations are not undertaken by a single reference center; they are performed
by different local pathologic institutes, using standardized, but sometimes different, analytic sets/kits.
However, the multicenter approach for bronchoscopy and the pathological analyses enables the results
to be more generalizable and represents a ‘real world’ setting.
Bleeding is the main side effect of bronchoscopic biopsy in visible endobronchial tumors.
No difference has been shown in clinically relevant bleeding between FB and CB in prospective
trials [39,74].
With this study’s focus on NSCLC diagnostics, we expect to obtain the essential information
needed to optimize therapy, and anticipate that the findings will have an impact on both disease
progression and survival in many NSCLC patients.
Author Contributions: M.H. and J.H. designed the study and wrote the study protocol. M.H., M.B., F.S. (Florian
Schimmele), W.S., F.S. (Franz Stanzel), C.P., K.D., L.H., R.M. (Robert Mueller), B.A., J.H. performed the bronchoscopy
at the participating centers. I.B., R.B., M.T., H.-U.S., H.B. and F.F. undertook the local pathology and molecular
genetic evaluation. R.M. (Rainer Muche) prepared the randomization, supervised the statistical analysis process
and performed the final statistical analysis. R.B., F.F. and L.Z. have given advice for the explorative research
concept; F.E. performed data collection and supported the participating centers. R.A.L. advised and reviewed
the writing process. All authors have read and agreed to the published version of the manuscript.
Funding: This investigator-initiated trial is supported by a grant from AstraZeneca. The funding source had no
role in the design of this study and will not have any role during its execution, analysis, interpretation of the data,
or its publication.
Acknowledgments: We thank all patients at the participating centers for their contribution to the study.
Conflicts of Interest: M.H., M.B. and J.H. have received personal fees from Erbe Elektromedizin GmbH for
workshops. I.B. has received personal fees from Novartis, BMS and AstraZeneca, K.D. has received travel grants
and lecture fees from ERBE and Olympus. No other authors have any conflicts of interests to declare.
Availability of Data and Materials: The datasets generated and/or analyzed during the current study are not
publicly available, in accordance with the ethics committee’s decision, but may be available from the corresponding
author on reasonable request and with the ethics committee’s consent.
References
1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA A Cancer J. Clin. 2014, 64, 9–29. [CrossRef]
[PubMed]
2. Cheng, T.Y.; Cramb, S.M.; Baade, P.D.; Youlden, D.R.; Nwogu, C.; Reid, M.E. The International Epidemiology
of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J. Thorac. Oncol. Off. Publ. Int. Assoc.
Study Lung Cancer 2016, 11, 1653–1671. [CrossRef]
Diagnostics 2020, 10, 459 11 of 15
3. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.;
Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer
(Oxf. Engl. 1990) 2013, 49, 1374–1403. [CrossRef]
4. Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.;
Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA A Cancer J. Clin. 2019. [CrossRef]
5. Meza, R.; Meernik, C.; Jeon, J.; Cote, M.L. Lung cancer incidence trends by gender, race and histology in
the United States, 1973–2010. PLoS ONE 2015, 10, e0121323. [CrossRef]
6. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA A Cancer J. Clin. 2009, 59,
225–249. [CrossRef]
7. Morgensztern, D.; Ng, S.H.; Gao, F.; Govindan, R. Trends in stage distribution for patients with non-small
cell lung cancer: A National Cancer Database survey. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung
Cancer 2010, 5, 29–33. [CrossRef]
8. Goldstraw, P.; Chansky, K.; Crowley, J.; Rami-Porta, R.; Asamura, H.; Eberhardt, W.E.; Nicholson, A.G.;
Groome, P.; Mitchell, A.; Bolejack, V. The IASLC Lung Cancer Staging Project: Proposals for Revision of
the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2016, 11, 39–51. [CrossRef]
9. Aisner, D.L.; Marshall, C.B. Molecular pathology of non-small cell lung cancer: A practical guide. Am. J.
Clin. Pathol. 2012, 138, 332–346. [CrossRef]
10. Lindeman, N.I.; Cagle, P.T.; Aisner, D.L.; Arcila, M.E.; Beasley, M.B.; Bernicker, E.H.; Colasacco, C.; Dacic, S.;
Hirsch, F.R.; Kerr, K.; et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for
Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists,
the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Arch. Pathol. Lab. Med. 2018, 142, 321–346. [CrossRef]
11. Yang, J.C.; Wu, Y.L.; Schuler, M.; Sebastian, M.; Popat, S.; Yamamoto, N.; Zhou, C.; Hu, C.P.; O’Byrne, K.;
Feng, J.; et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma
(LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials.
Lancet Oncol. 2015, 16, 141–151. [CrossRef]
12. Zhou, C.; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive
non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 2011, 12, 735–742. [CrossRef]
13. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.;
Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre,
open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13, 239–246. [CrossRef]
14. Wu, Y.L.; Zhou, C.; Liam, C.K.; Wu, G.; Liu, X.; Zhong, Z.; Lu, S.; Cheng, Y.; Han, B.; Chen, L.; et al. First-line
erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell
lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann. Oncol. Off. J. Eur.
Soc. Med Oncol. 2015, 26, 1883–1889. [CrossRef]
15. Fukuoka, M.; Wu, Y.L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.S.; Sriuranpong, V.; Chao, T.Y.;
Nakagawa, K.; Chu, D.T.; Saijo, N.; et al. Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
2011, 29, 2866–2874. [CrossRef]
16. Sequist, L.V.; Yang, J.C.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.M.;
Boyer, M.; et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung
adenocarcinoma with EGFR mutations. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31, 3327–3334.
[CrossRef]
17. Yang, J.C.; Hirsh, V.; Schuler, M.; Yamamoto, N.; O’Byrne, K.J.; Mok, T.S.; Zazulina, V.; Shahidi, M.;
Lungershausen, J.; Massey, D.; et al. Symptom control and quality of life in LUX-Lung 3: A phase III study
of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31, 3342–3350. [CrossRef]
Diagnostics 2020, 10, 459 12 of 15
18. Mok, T.S.; Cheng, Y.; Zhou, X.; Lee, K.H.; Nakagawa, K.; Niho, S.; Lee, M.; Linke, R.; Rosell, R.; Corral, J.; et al.
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in
Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J. Clin. Oncol. Off. J.
Am. Soc. Clin. Oncol. 2018, 36, 2244–2250. [CrossRef]
19. Zhou, C.; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; et al. Final
overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line
treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann.
Oncol. Off. J. Eur. Soc. Med Oncol. 2015, 26, 1877–1883. [CrossRef] [PubMed]
20. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.;
Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl.
J. Med. 2009, 361, 947–957. [CrossRef] [PubMed]
21. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.;
Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated
EGFR. N. Engl. J. Med. 2010, 362, 2380–2388. [CrossRef]
22. Yoneda, K.; Imanishi, N.; Ichiki, Y.; Tanaka, F. A liquid biopsy in primary lung cancer. Surg. Today 2019, 49,
1–14. [CrossRef]
23. Castello, A.; Russo, C.; Grizzi, F.; Qehajaj, D.; Lopci, E. Prognostic Impact of Intratumoral Heterogeneity
Based on Fractal Geometry Analysis in Operated NSCLC Patients. Mol. Imaging Biol. Mib Off. Publ. Acad.
Mol. Imaging 2018. [CrossRef]
24. Chen, Z.Y.; Zhong, W.Z.; Zhang, X.C.; Su, J.; Yang, X.N.; Chen, Z.H.; Yang, J.J.; Zhou, Q.; Yan, H.H.;
An, S.J.; et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of
lung adenocarcinomas. Oncologist 2012, 17, 978–985. [CrossRef] [PubMed]
25. Guo, L.; Chen, Z.; Xu, C.; Zhang, X.; Yan, H.; Su, J.; Yang, J.; Xie, Z.; Guo, W.; Li, F.; et al. Intratumoral
heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer
2019, 19, 369. [CrossRef] [PubMed]
26. Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.;
Johnson, D.H.; Mitter, R.; Rosenthal, R.; et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N. Engl.
J. Med. 2017, 376, 2109–2121. [CrossRef]
27. Jia, Q.; Wu, W.; Wang, Y.; Alexander, P.B.; Sun, C.; Gong, Z.; Cheng, J.N.; Sun, H.; Guan, Y.; Xia, X.; et al.
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat.
Commun. 2018, 9, 5361. [CrossRef]
28. Kwon, D.; Koh, J.; Kim, S.; Go, H.; Kim, Y.A.; Keam, B.; Kim, T.M.; Kim, D.W.; Jeon, Y.K.; Chung, D.H. MET
exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas:
An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer
(Amst. Neth.) 2017, 106, 131–137. [CrossRef]
29. Mansuet-Lupo, A.; Zouiti, F.; Alifano, M.; Tallet, A.; Charpentier, M.C.; Ducruit, V.; Devez, F.; Lemaitre, F.;
Laurent-Puig, P.; Damotte, D.; et al. Intratumoral distribution of EGFR mutations and copy number in
metastatic lung cancer, what impact on the initial molecular diagnosis? J. Transl. Med. 2014, 12, 131.
[CrossRef]
30. Nakamura, S.; Hayashi, K.; Imaoka, Y.; Kitamura, Y.; Akazawa, Y.; Tabata, K.; Groen, R.; Tsuchiya, T.;
Yamasaki, N.; Nagayasu, T.; et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression
is common in lung cancer. PLoS ONE 2017, 12, e0186192. [CrossRef]
31. Remon, J.; Majem, M. EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors
of non small cell lung cancer: A clue to overcoming resistance. Transl. Lung Cancer Res. 2013, 2, 445–448.
[CrossRef]
32. Soucheray, M.; Capelletti, M.; Pulido, I.; Kuang, Y.; Paweletz, C.P.; Becker, J.H.; Kikuchi, E.; Xu, C.; Patel, T.B.;
Al-Shahrour, F.; et al. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance
Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Res. 2015, 75, 4372–4383. [CrossRef]
33. Taniguchi, K.; Okami, J.; Kodama, K.; Higashiyama, M.; Kato, K. Intratumor heterogeneity of epidermal
growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci.
2008, 99, 929–935. [CrossRef]
Diagnostics 2020, 10, 459 13 of 15
34. Zhang, L.L.; Kan, M.; Zhang, M.M.; Yu, S.S.; Xie, H.J.; Gu, Z.H.; Wang, H.N.; Zhao, S.X.; Zhou, G.B.;
Song, H.D.; et al. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in
TP53-driven non-small cell lung cancer. Int. J. Cancer 2017, 140, 103–108. [CrossRef]
35. Leighl, N.B.; Rekhtman, N.; Biermann, W.A.; Huang, J.; Mino-Kenudson, M.; Ramalingam, S.S.; West, H.;
Whitlock, S.; Somerfield, M.R. Molecular testing for selection of patients with lung cancer for epidermal
growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society
of Clinical Oncology endorsement of the College of American Pathologists/International Association for
the study of lung cancer/association for molecular pathology guideline. J. Clin. Oncol. Off. J. Am. Soc. Clin.
Oncol. 2014, 32, 3673–3679. [CrossRef]
36. Lindeman, N.I.; Cagle, P.T.; Beasley, M.B.; Chitale, D.A.; Dacic, S.; Giaccone, G.; Jenkins, R.B.;
Kwiatkowski, D.J.; Saldivar, J.S.; Squire, J.; et al. Molecular testing guideline for selection of lung cancer
patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists,
International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac.
Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2013, 8, 823–859. [CrossRef]
37. Kalemkerian, G.P.; Narula, N.; Kennedy, E.B.; Biermann, W.A.; Donington, J.; Leighl, N.B.; Lew, M.; Pantelas, J.;
Ramalingam, S.S.; Reck, M.; et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer
for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement
of the College of American Pathologists/International Association for the Study of Lung Cancer/Association
for Molecular Pathology Clinical Practice Guideline Update. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018,
36, 911–919. [CrossRef]
38. Liu, Y.; Dong, Z.; Jiang, T.; Hou, L.; Wu, F.; Gao, G.; He, Y.; Zhao, J.; Li, X.; Zhao, C.; et al. Heterogeneity of
PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients
With Resected Lung Adenosquamous Carcinoma. Clin. Lung Cancer 2018, 19, e421–e430. [CrossRef]
39. Hetzel, J.; Eberhardt, R.; Herth, F.J.; Petermann, C.; Reichle, G.; Freitag, L.; Dobbertin, I.; Franke, K.J.;
Stanzel, F.; Beyer, T.; et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: A multicentre
trial. Eur. Respir. J. 2012, 39, 685–690. [CrossRef] [PubMed]
40. Haentschel, M.; Boeckeler, M.; Ehab, A.; Wagner, R.; Spengler, W.; Steger, V.; Boesmueller, H.; Horger, M.;
Lewis, R.A.; Fend, F.; et al. Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.
Lung Cancer (Amst. Neth.) 2020, 141, 56–63. [CrossRef] [PubMed]
41. Du Rand, I.A.; Barber, P.V.; Goldring, J.; Lewis, R.A.; Mandal, S.; Munavvar, M.; Rintoul, R.C.; Shah, P.L.;
Singh, S.; Slade, M.G.; et al. British Thoracic Society guideline for advanced diagnostic and therapeutic
flexible bronchoscopy in adults. Thorax 2011, 66 (Suppl. 3), iii1–iii21. [CrossRef]
42. Du Rand, I.A.; Blaikley, J.; Booton, R.; Chaudhuri, N.; Gupta, V.; Khalid, S.; Mandal, S.; Martin, J.; Mills, J.;
Navani, N.; et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: Accredited
by NICE. Thorax 2013, 68 (Suppl. 1), i1–i44. [CrossRef] [PubMed]
43. Hetzel, J.; Hetzel, M.; Hasel, C.; Moeller, P.; Babiak, A. Old meets modern: The use of traditional cryoprobes
in the age of molecular biology. Respir. Int. Rev. Thorac. Dis. 2008, 76, 193–197. [CrossRef] [PubMed]
44. Colella, S.; Haentschel, M.; Shah, P.; Poletti, V.; Hetzel, J. Transbronchial Lung Cryobiopsy in Interstitial Lung
Diseases: Best Practice. Respir. Int. Rev. Thorac. Dis. 2018, 95, 383–391. [CrossRef]
45. Wahidi, M.M.; Herth, F.; Yasufuku, K.; Shepherd, R.W.; Yarmus, L.; Chawla, M.; Lamb, C.; Casey, K.R.;
Patel, S.; Silvestri, G.A.; et al. Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle
Aspiration: CHEST Guideline and Expert Panel Report. Chest 2016, 149, 816–835. [CrossRef]
46. van der Heijden, E.H.; Casal, R.F.; Trisolini, R.; Steinfort, D.P.; Hwangbo, B.; Nakajima, T.;
Guldhammer-Skov, B.; Rossi, G.; Ferretti, M.; Herth, F.F.; et al. Guideline for the acquisition and preparation
of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for
the diagnosis and molecular testing of patients with known or suspected lung cancer. Respir. Int. Rev.
Thorac. Dis. 2014, 88, 500–517. [CrossRef]
47. Buttner, R.; Wolf, J.; Kron, A. [The national Network Genomic Medicine (nNGM): Model for innovative
diagnostics and therapy of lung cancer within a public healthcare system]. Der Pathol. 2019, 40, 276–280.
[CrossRef]
48. National Network Genomic Medicine (nNGM). Centralized Testing—Decentral Treatment. Available online:
https://www.nngm.de/en/ (accessed on 25 June 2020).
Diagnostics 2020, 10, 459 14 of 15
49. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.;
Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139.
[CrossRef]
50. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.;
Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.
Science (N. Y.) 2004, 304, 1497–1500. [CrossRef]
51. Kobayashi, T.; Koizumi, T.; Agatsuma, T.; Yasuo, M.; Tsushima, K.; Kubo, K.; Eda, S.; Kuraishi, H.; Koyama, S.;
Hachiya, T.; et al. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung
cancer. Cancer Chemother. Pharmacol. 2012, 69, 1241–1246. [CrossRef]
52. Tsunoda, A.; Morikawa, K.; Inoue, T.; Miyazawa, T.; Hoshikawa, M.; Takagi, M.; Mineshita, M. A prospective
observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
BMC Cancer 2019, 19, 546. [CrossRef]
53. Naito, J.; Toyoda, T.; Nakajima, T.; Fujiwara, T.; Iwasawa, S.; Suzuki, H.; Takiguchi, Y.; Yoshino, I. A Repeated
Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung
Cancer Patient. J. Bronchol. Interv. Pulmonol. 2019, 26, 129–131. [CrossRef]
54. Wisniewski, P.; Glogowski, M.; Olszewski, W. Assessment of diagnostic value of cytological examination in
lung carcinoma in own material obtained by EBUS and EUS methods. Pol. J. Pathol. Off. J. Pol. Soc. Pathol.
2018, 69, 278–284. [CrossRef] [PubMed]
55. Raad, S.; Hanna, N.; Jalal, S.; Bendaly, E.; Zhang, C.; Nuguru, S.; Oueini, H.; Diab, K. Endobronchial
Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung
Non-Small-Cell Carcinoma. South. Med. J. 2018, 111, 484–488. [CrossRef]
56. Goag, E.K.; Lee, J.M.; Chung, K.S.; Kim, S.Y.; Leem, A.Y.; Song, J.H.; Jung, J.Y.; Park, M.S.; Chang, Y.S.;
Kim, Y.S.; et al. Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired
Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. J. Cancer 2018, 9, 1113–1120.
[CrossRef] [PubMed]
57. Stoy, S.P.; Segal, J.P.; Mueller, J.; Furtado, L.V.; Vokes, E.E.; Patel, J.D.; Murgu, S. Feasibility of Endobronchial
Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing
in Non-small-cell Lung Cancer. Clin. Lung Cancer 2018, 19, 230–238.e232. [CrossRef]
58. Bonifazi, M.; Tramacere, I.; Zuccatosta, L.; Mei, F.; Sediari, M.; Paonessa, M.C.; Gasparini, S. Conventional
versus Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymph
Adenopathies: A Randomized Controlled Trial. Respir. Int. Rev. Thorac. Dis. 2017, 94, 216–223. [CrossRef]
59. Kirita, K.; Izumo, T.; Matsumoto, Y.; Hiraishi, Y.; Tsuchida, T. Bronchoscopic Re-biopsy for Mutational
Analysis of Non-small Cell Lung Cancer. Lung 2016, 194, 371–378. [CrossRef]
60. Izumo, T.; Matsumoto, Y.; Chavez, C.; Tsuchida, T. Re-biopsy by endobronchial ultrasound procedures for
mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment. BMC Pulm.
Med. 2016, 16, 106. [CrossRef]
61. Rooper, L.M.; Nikolskaia, O.; Carter, J.; Ning, Y.; Lin, M.T.; Maleki, Z. A single EBUS-TBNA procedure can
support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene
analyses in the majority of non-small cell lung cancer cases. Hum. Pathol. 2016, 51, 139–145. [CrossRef]
62. Casadio, C.; Guarize, J.; Donghi, S.; Di Tonno, C.; Fumagalli, C.; Vacirca, D.; Dell’Orto, P.; De Marinis, F.;
Spaggiari, L.; Viale, G.; et al. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung
Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. Am. J. Clin. Pathol. 2015,
144, 629–634. [CrossRef]
63. Oki, M.; Saka, H.; Ando, M.; Kitagawa, C.; Kogure, Y.; Seki, Y. Endoscopic ultrasound-guided fine needle
aspiration and endobronchial ultrasound-guided transbronchial needle aspiration: Are two better than
one in mediastinal staging of non-small cell lung cancer? J. Thorac. Cardiovasc. Surg. 2014, 148, 1169–1177.
[CrossRef]
64. Navani, N.; Brown, J.M.; Nankivell, M.; Woolhouse, I.; Harrison, R.N.; Jeebun, V.; Munavvar, M.; Ng, B.J.;
Rassl, D.M.; Falzon, M.; et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration
specimens for subtyping and genotyping of non-small cell lung cancer: A multicenter study of 774 patients.
Am. J. Respir. Crit. Care Med. 2012, 185, 1316–1322. [CrossRef]
Diagnostics 2020, 10, 459 15 of 15
65. Schmid-Bindert, G.; Wang, Y.; Jiang, H.; Sun, H.; Henzler, T.; Wang, H.; Pilz, L.R.; Ren, S.; Zhou, C.
EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small
biopsies in non-small cell lung cancer patients—A comparative study of three different minimal invasive
sampling methods. PLoS ONE 2013, 8, e77948. [CrossRef]
66. Navani, N.; Nankivell, M.; Lawrence, D.R.; Lock, S.; Makker, H.; Baldwin, D.R.; Stephens, R.J.; Parmar, M.K.;
Spiro, S.G.; Morris, S.; et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided
transbronchial needle aspiration compared with conventional approaches: An open-label, pragmatic,
randomised controlled trial. Lancet. Respir. Med. 2015, 3, 282–289. [CrossRef]
67. Cheng, Y.; Wang, Y.; Zhao, J.; Liu, Y.; Gao, H.; Ma, K.; Zhang, S.; Xin, H.; Liu, J.; Han, C.; et al. Real-world
EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter,
non-interventional study. Thorac. Cancer 2018, 9, 1461–1469. [CrossRef]
68. Hong, M.H.; Kim, H.R.; Ahn, B.C.; Heo, S.J.; Kim, J.H.; Cho, B.C. Real-World Analysis of the Efficacy of
Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung
Cancer. Yonsei Med. J. 2019, 60, 525–534. [CrossRef] [PubMed]
69. Komiya, K.; Nakashima, C.; Nakamura, T.; Hirakawa, H.; Abe, T.; Ogusu, S.; Takahashi, K.; Takeda, Y.;
Egashira, Y.; Kimura, S.; et al. Current Status and Problems of T790M Detection, a Molecular Biomarker of
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. Anticancer Res.
2018, 38, 3559–3566. [CrossRef]
70. Kim, T.O.; Oh, I.J.; Kho, B.G.; Park, H.Y.; Chang, J.S.; Park, C.K.; Shin, H.J.; Lim, J.H.; Kwon, Y.S.; Kim, Y.I.; et al.
Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer. Thorac. Cancer
2018, 9, 856–864. [CrossRef]
71. Chougule, A.; Basak, S. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review
of sensitive methods for analysis of tissue and liquid biopsy samples. Indian J. Cancer 2017, 54, S45–S54.
[CrossRef]
72. Zanwar, S.; Noronha, V.; Joshi, A.; Patil, V.M.; Chougule, A.; Kumar, R.; More, S.; Goud, S.; Janu, A.;
Mahajan, A.; et al. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung
cancer: Feasibility, limitations, and clinical utility in Indian patients. Indian J. Cancer 2017, 54, 280–284.
[CrossRef] [PubMed]
73. Clery, E.; Pisapia, P.; Feliciano, S.; Vigliar, E.; Marano, A.; De Luca, C.; Malapelle, U.; Troncone, G.;
Bellevicine, C. There is still a role for cytology in the ‘liquid biopsy’ era. A lesson from a TKI-treated patient
showing adenocarcinoma to squamous cell carcinoma transition during disease progression. J. Clin. Pathol.
2017, 70, 798–802. [CrossRef] [PubMed]
74. Ehab, A.; Khairy El-Badrawy, M.; Abdelhamed Moawad, A.; El-Dosouky Abo-Shehata, M. Cryobiopsy
versus forceps biopsy in endobronchial lesions, diagnostic yield and safety. Adv. Respir. Med. 2017, 85,
301–306. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
